UNINA participants have long-lasting expertise in developing advanced delivery strategies for nucleic acids, covering the crucial aspects of their translation to the patient’s bedside. Their current activities are focused on developing polymeric, lipid, and peptide-based nanoplatforms for precision delivery, engineering of AAV, nanoparticle production technologies, paper-based sensors, and in vitro/in vivo models to test delivery efficiency with the support of omics sciences.

National Research Council of Italy (CNR) participants are experts in developing inorganic nanomaterials for drug delivery, novel genetic methodologies for in vivo neuronal cell reprogramming based on AAV9 vectors with superior brain transduction, and the application of extracellular vesicles of natural origin as delivery tools.

Italian Institute of Technology (IIT) participants have consolidated expertise in engineering nanoplatforms for precision medicine, GLP production by microfluidics, and additive manufacturing of microneedles for drug delivery.

University of Milan (UNIMI) participants have strong experience with extracellular vesicles that are close to the clinical application. Leishmania tarentolae-derived microvesicles, and synthetic delivery platforms, such as lipid nanoparticles and lipopolyplexes were developed according to the European Medicines Agency (EMA) regulatory framework. Furthermore, the participants have consolidated skills in developing freeze-drying methods to stabilize nanoparticulate drug delivery systems and avoid cold chain transport.

University of Milano-Bicocca (UNIMIB) participants are experts in the design, implementation, and study of non-viral biocompatible nanosystems for nucleic acid delivery in the treatment of oncological, inflammatory, and neurodegenerative diseases. UNIMIB takes advantage of its cutting-edge automated platforms for the synthesis and characterization of nanocarriers for nucleic acid delivery.

University of Palermo (UNIPA) participants have consolidated skills in the development of tailor-made biopolymers able to integrate nanostructures, such as carbon nanodots, to form interpolyelectrolyte complexes and to decorate extracellular vesicles for the development of nanoplatforms for RNA/DNA delivery.

University of Padua (UNIPD) participants have expertise in the generation of innovative supramolecular platforms for cell-selective and controlled RNA/DNA delivery (polyplexes, lipoplexes, and nanoparticles). Furthermore, they have expertise in biological characterization of nanosystems by preclinical tools, (i.e. 2D/3D cells, zebrafish) and advanced ex-vivo/in-vivo organ perfusion.

University of Pisa (UNIPI) participants have consolidated expertise in extracellular vesicles (naturally obtained by specific cell culture) or camouflaged soft nanosystems (obtained by coating natural cationic polymers, lipids, or cyclodextrins with specific cell membrane fragments).

University of Salerno (UNISA) participants have consolidated skills in advanced technologies for powder production (supercritical fluids), microfluidics, and the evaluation of Absorption Distribution Metabolism Excretion Toxicity (ADMET) by mass spectrometry (MS) and liquid chromatography – mass spectrometry (LC-MS) methods.

University of Turin (UNITO) researchers have robust expertise in developing delivery systems based on the engineering of naturally occurring extracellular vesicles and nanoplatforms.

Antares Vision Group is active in the pharmaceutical market and guarantees the protection of products, profit, people, and the planet through inspection systems for quality control, Track & Trace solutions for anti-counterfeiting and supply chain transparency, smart data management tools for maximized efficiency and digitalization of the supply chain, from raw materials to consumer.

Chiesi Group is an international research-focused biopharmaceuticals group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment.

With its headquarters in Parma (Italy) and with over 85 years of experience, Chiesi operates within 31 countries and has more than 6,500 employees. Its research and development center in Parma works alongside six other important R&D hubs in France, the USA, Canada, China, the UK, and Sweden.

Dompè Pharmaceuticals is recognized for its expertise in research, development, and production of innovative therapies across various therapeutic areas. Specializing in biotechnology, it has notable proficiency in developing treatments for rare diseases, ophthalmology, and diabetes, focusing on biopharmaceuticals, gene therapy, and regenerative medicine. Dompé Pharmaceuticals is known for its commitment to scientific innovation, leveraging cutting-edge technologies and collaborations to advance novel therapeutic solutions for unmet medical needs.

Stevanato Group is a global leader in providing advanced solutions for drug containment, drug delivery systems, and pharmaceutical services. With a specialization in glass primary packaging for pharmaceuticals and diagnostics, Stevanato excels in producing high-quality innovative solutions like glass containers, syringes, and cartridges for injectable drugs. The company’s expertise spans engineering, manufacturing, and delivering state-of-the-art solutions in drug packaging, drug delivery devices, and analytical services, which cater to the needs of pharmaceutical companies worldwide. Stevanato is renowned for its focus on innovation, sustainability, and commitment to advancing technologies in pharmaceutical packaging and drug delivery systems.

Takis Biotech is a biotechnology company at the forefront of vaccine and immunotherapy research. Renowned for its expertise in developing cutting-edge technologies for cancer immunotherapy, Takis Biotech focuses on creating innovative therapies using DNA-based vaccines and gene therapy approaches. With a primary focus on oncology and infectious diseases, Takis Biotech specializes in designing personalized and targeted immunotherapies to combat various cancers and emerging infectious agents. The company’s proficiency lies in preclinical research, vaccine development, and advancing novel therapeutic strategies through collaborations and innovative scientific advancements. Takis Biotech’s commitment to groundbreaking research places it as a pivotal player in immunotherapy and vaccine development.